Griseofulvin

Griseofulvin is only approved as a systemic (oral) agent and is indicated for the treatment of dermatophytoses of the skin, hair, and nails, which is severe or refractory to topical therapy. Specifically, this drug treats tinea (corporis, pedis, cruris, barbae, capitis, and unguium) where topical therapy has failed or is inappropriate

Cautions:

• Rarely aggravation or precipitation of SLE

Contra-indications:

• Porphyria
• Pregnancy
• Liver failure

Side-effects:

• Rashes
• Headache
• Nausea and vomiting
• Photosensitivity

Routes of administration:

• Oral
  • Tablets
  • Suspension

Check with summary of product characteristics before prescribing this drug.

References:

1. McKeny T et al. Antifungal Antibiotics. Treasure Island (FL): StatPearls Publishing. 2025 Jan.
2. British National Formulary (BNF); NICE Evidence Services (UK access only).